Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody drug offers hope for stubborn blood disorders

NCT ID NCT07175493

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 21 times

Summary

This study tests a new drug called CM336 in people with autoimmune cytopenia, a condition where the immune system attacks blood cells. The drug aims to control the disease by targeting certain immune cells. About 158 adults with relapsed or refractory forms of immune thrombocytopenia, autoimmune hemolytic anemia, or Evans syndrome will participate. The main goals are to check safety and see if blood cell counts improve.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Blood Disease Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Heping Hospital Affiliated to Changzhi Medical College

    RECRUITING

    Changzhi, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.